JP2009507758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507758A5 JP2009507758A5 JP2008511498A JP2008511498A JP2009507758A5 JP 2009507758 A5 JP2009507758 A5 JP 2009507758A5 JP 2008511498 A JP2008511498 A JP 2008511498A JP 2008511498 A JP2008511498 A JP 2008511498A JP 2009507758 A5 JP2009507758 A5 JP 2009507758A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- hydrogen
- unsubstituted
- alkyl
- unsubstituted lower
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- -1 hydroxy, formyl Chemical group 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 125000001589 carboacyl group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000001118 alkylidene group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- VBXYJTRDAAYDCJ-SFHVURJKSA-N chembl2170284 Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC[C@@H](CO)NC3=2)C=2C=CC(F)=CC=2)=N1 VBXYJTRDAAYDCJ-SFHVURJKSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- RPPJHJYVSWATLF-UHFFFAOYSA-N 6-[2'-(4-fluorophenyl)spiro[1,3-dioxolane-2,6'-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidine]-3'-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC4(CNC3=2)OCCO4)C=2C=CC(F)=CC=2)=N1 RPPJHJYVSWATLF-UHFFFAOYSA-N 0.000 claims 1
- KTPOXQVGTABKFF-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)CNC3=2)C=2C(=CC(F)=CC=2)F)=N1 KTPOXQVGTABKFF-UHFFFAOYSA-N 0.000 claims 1
- KDWXNVQYEFVHPZ-UHFFFAOYSA-N 6-[2-(2,4-difluorophenyl)-6-[(dimethylamino)methyl]-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound N=1N2CC(CN(C)C)CNC2=C(C2=NN(C(=O)C=C2)C=2C(=CC=CC=2)C)C=1C1=CC=C(F)C=C1F KDWXNVQYEFVHPZ-UHFFFAOYSA-N 0.000 claims 1
- SUDIDDCAFMIBIF-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6,6-dimethyl-5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=C(C=CC=C1)N1N=C(C=CC1=O)C1=C2NCC(C)(C)CN2N=C1C1=CC=C(F)C=C1 SUDIDDCAFMIBIF-UHFFFAOYSA-N 0.000 claims 1
- LYHNSWOZRDSWLX-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(CO)CNC3=2)C=2C=CC(F)=CC=2)=N1 LYHNSWOZRDSWLX-UHFFFAOYSA-N 0.000 claims 1
- QXYRMVUWXFWUKP-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)-6-hydroxy-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC(O)CNC3=2)C=2C=CC(F)=CC=2)=N1 QXYRMVUWXFWUKP-UHFFFAOYSA-N 0.000 claims 1
- SXKMPLDBLZUHKW-UHFFFAOYSA-N 6-[2-(4-fluorophenyl)spiro[5,7-dihydro-4H-pyrazolo[1,5-a]pyrimidine-6,4'-oxane]-3-yl]-2-(2-methylphenyl)pyridazin-3-one Chemical compound CC1=CC=CC=C1N1C(=O)C=CC(C=2C(=NN3CC4(CCOCC4)CNC3=2)C=2C=CC(F)=CC=2)=N1 SXKMPLDBLZUHKW-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005281 alkyl ureido group Chemical group 0.000 claims 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282505P | 2005-09-01 | 2005-09-01 | |
| US60/712,825 | 2005-09-01 | ||
| PCT/JP2006/317691 WO2007026950A1 (en) | 2005-09-01 | 2006-08-31 | Pyridazinone derivatives used for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009507758A JP2009507758A (ja) | 2009-02-26 |
| JP2009507758A5 true JP2009507758A5 (enExample) | 2012-08-30 |
| JP5066516B2 JP5066516B2 (ja) | 2012-11-07 |
Family
ID=37607561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511498A Expired - Fee Related JP5066516B2 (ja) | 2005-09-01 | 2006-08-31 | 疼痛の治療に用いられるピリダジノン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090042856A1 (enExample) |
| EP (1) | EP1919919A1 (enExample) |
| JP (1) | JP5066516B2 (enExample) |
| KR (1) | KR20080049758A (enExample) |
| CN (1) | CN101268079B (enExample) |
| AU (1) | AU2006285599A1 (enExample) |
| BR (1) | BRPI0617100A2 (enExample) |
| CA (1) | CA2620740A1 (enExample) |
| IL (1) | IL189697A0 (enExample) |
| NO (1) | NO20081572L (enExample) |
| RU (1) | RU2008112290A (enExample) |
| TW (1) | TW200745034A (enExample) |
| WO (1) | WO2007026950A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200904421A (en) * | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN103180300B (zh) * | 2010-09-08 | 2015-10-07 | 住友化学株式会社 | 制备哒嗪酮化合物的方法和其中间体 |
| UA114490C2 (uk) | 2011-10-06 | 2017-06-26 | Байєр Інтеллектуал Проперті Гмбх | Гетероциклілпіри(mі)динілпіразоли як фунгіциди |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| CN106146404B (zh) * | 2015-04-15 | 2020-03-20 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| UA125852C2 (uk) | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| US20040152659A1 (en) * | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| AR023966A1 (es) * | 1999-05-12 | 2002-09-04 | Fujisawa Pharmaceutical Co | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion |
| AUPQ441499A0 (en) * | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
-
2006
- 2006-08-31 TW TW095132103A patent/TW200745034A/zh unknown
- 2006-08-31 AU AU2006285599A patent/AU2006285599A1/en not_active Abandoned
- 2006-08-31 CN CN2006800322174A patent/CN101268079B/zh not_active Expired - Fee Related
- 2006-08-31 RU RU2008112290/04A patent/RU2008112290A/ru not_active Application Discontinuation
- 2006-08-31 EP EP06797567A patent/EP1919919A1/en not_active Withdrawn
- 2006-08-31 KR KR1020087007056A patent/KR20080049758A/ko not_active Ceased
- 2006-08-31 CA CA002620740A patent/CA2620740A1/en not_active Abandoned
- 2006-08-31 US US12/063,766 patent/US20090042856A1/en not_active Abandoned
- 2006-08-31 JP JP2008511498A patent/JP5066516B2/ja not_active Expired - Fee Related
- 2006-08-31 BR BRPI0617100-1A patent/BRPI0617100A2/pt not_active IP Right Cessation
- 2006-08-31 WO PCT/JP2006/317691 patent/WO2007026950A1/en not_active Ceased
-
2008
- 2008-02-24 IL IL189697A patent/IL189697A0/en unknown
- 2008-03-31 NO NO20081572A patent/NO20081572L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025535046A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質の複素環阻害剤及びその使用 | |
| JP7860103B2 (ja) | 複素環式スピロ化合物及びその使用方法 | |
| JP2019514878A5 (enExample) | ||
| EP2552907B1 (en) | Pyridyltriazoles | |
| JP2012501312A5 (enExample) | ||
| JP2009538896A5 (enExample) | ||
| RU2012152548A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| RU2012136643A (ru) | [5,6]- гетероциклическое соединение | |
| JP2016525072A (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP2021506816A5 (enExample) | ||
| JP2014522855A5 (enExample) | ||
| ME02203B (me) | Hinolin i hinoksalin derivati kao inhibitori kinaza | |
| JP2003531210A5 (enExample) | ||
| JP2019523233A5 (enExample) | ||
| JP2011500774A5 (enExample) | ||
| JP2011503166A5 (enExample) | ||
| ME01290B (me) | Piradizinski derivati kao smo inhibitori | |
| HRP20180080T1 (hr) | Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze | |
| JP2011506466A5 (enExample) | ||
| RU2006134021A (ru) | Производные гетероарил-конденсированного пиразола | |
| CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
| JP2013526536A5 (enExample) | ||
| HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
| RU2008136784A (ru) | Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака | |
| JP2020526549A5 (enExample) |